ATCC 2023 Holiday Shipping Schedule: We will be closed from December 22nd to January 1st. To ensure timely delivery, please submit orders in accordance with the following: Domestic orders no later than December 15th for shipment by December 20th 2023; International orders no later than December 12th for shipment by the first week of January 2024. We will resume our normal shipping schedule on January 2nd, 2024. Thank you for your cooperation. 

ATCC ATCC Logo 0
  • Quick Order
  • Careers
  • Support
Green mesenchymal IPS stem cells.

Expand Your Cell-based Assays with an Unlimited, Biologically Relevant Resource

July 22, 2021, at 12:00 PM ET

Abstract

Toxicology and cancer researchers alike are challenged by the lack of a consistent source of cells with high physiological relevance for their cell-based assays. The source tissue for primary cells comes from a variety of donors, which can introduce interexperimental variability and confound experimental results. Differentiated induced pluripotent stem cell (iPSC)-derived cells fulfill the need for a consistent source of cells and physiological relevance. iPSCs are able to be generated in large cell numbers from a single clone, providing the needed consistency. Further, iPSCs can be differentiated into a variety of desired, functional cell types, affording the necessary biological relevance. Here we provide data demonstrating how differentiated iPSC-derived cells can be incorporated into immunoassays or further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.

Key Points

  • Differentiated iPSCs lend the ability to run large toxicity studies and drug screens on highly biologically relevant cells.
  • ATCC iPSCs were used as the source for three types of differentiated cells: CD34+ progenitors, mesenchymal stem cells (MSCs), and monocytes.
  • ATCC R&D scientists have generated in-depth data showing the iPSC-derived cells can be incorporated into immunoassays and further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.

Watch The Presentation

Presenter

Brian Shapiro, headshot.

Brian Shapiro, PhD

Marketing Segment Manager, Oncology, ATCC

Brian A Shapiro, PhD, works to communicate the scientific breakthroughs of ATCC’s product development laboratories to the biomedical research community. Brian is the Executive Producer of ATCC's Podcast, Behind the Biology. Previously, he worked at Virginia Commonwealth University, where he investigated the role of pre-mRNA splicing in the multi-drug resistance of lung cancer. Dr. Shapiro attended the Medical College of Georgia, where his research focused on adrenal physiology as well as diseases of the epidermis.